📢 Recent Milestones (2025-2026):
In January 2026, AliveCor announced FDA clearance for the next generation of KAI 12L, the AI powering the Kardia 12L ECG System, adding five new cardiac determinations—short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation, and right axis deviation—bringing the total to 39 FDA-cleared determinations. In 2025, CMS approved Medicare payment for Kardia 12L in hospital outpatient settings following the establishment of Category III CPT codes by the AMA in 2024. Since its June 2024 launch, Kardia 12L has been adopted by over 250 clinical practices and identified more than 4,000 cases of myocardial infarction and ischemia.
Company Overview (Updated April 2026)
AliveCor, Inc. is a leADINg health technology company focused on advancing cardiology care through innovative, portAble ECG devices and AI-powered analytics. Founded in 2010 and headquartered in Mountain View, California, the company is recognized globally for creating the first FDA-cleared mobile ECG solution and transforming cardiac care through mACHine learning technology.
The company's mission is to enable proactive heart care by providing clinical-quality ECG recording capabilities to consumers and healthcare providers alike. AliveCor's FDA-cleared Kardia devices are the most clinically validated mobile EKG solutions on the market, recommended by leading cardiologists and used worldwide for accurate detection of atrial fibrillation (AFib), bradycardia, tachycardia, and other cardiac conditions.
Corporate History & Funding
Founding & Early Development:
- 2010: Founded by Dr. David Albert in San Francisco, California, with the vision of transforming smartphones into clinical-quality ECG recorders
- 2012: Raised $10.5 million in Series B funding led by Khosla Ventures and Qualcomm Ventures
- 2014: Received first FDA clearance for algorithm to detect atrial fibrillation (AFib), the most common cardiac arrhythmia
- 2017: Secured $30 million Series D funding led by Omron Healthcare and Mayo Clinic; launched Kardia Pro AI platform for stroke prevention
- 2020: Closed $65 million Series E financing led by Omron, Khosla Ventures, WP Global Partners, Qualcomm Ventures, and Bold Capital Partners to accelerate remote cardiology platform growth
- 2022: Completed Series F funding round led by GE Healthcare (undisclosed amount)
- Total Funding: Over $108.5 million raised across multiple rounds
Core Product Portfolio
KardiaMobile Series (Personal ECG Devices)
KardiaMobile: The original single-lead personal ECG device, FDA-cleared for detection of atrial fibrillation, bradycardia, and tachycardia. The credit card-sized device pairs with smartphones to provide instant cardiac analysis.
KardiaMobile 6L: Advanced six-lead ECG device allowing cardiologists to view electrical heart activity from six perspectives, enabling detection of a broader range of heart conditions including AFib, PVCs, and other arrhythmias.
Key Features:
- Instant detection of AFib, bradycardia, tachycardia, and normal sinus rhythm
- FDA-cleared AI algorithms for accurate cardiac analysis
- Integration with Kardia app for seamless data recording and sharing
KardiaBand (Discontinued Product Line)
KardiaBand was the first FDA-cleared medical device accessory for Apple Watch (approved November 2017). The integrated sensor allowed Apple Watch users to capture medical-grade ECG readings directly from their wrists. The product has since been discontinued as Apple integrated similar ECG functionality directly into the Apple Watch Series 4 and later models.
Kardia 12L ECG System (Clinical-Grade Innovation)
Launch: June 2024
Kardia 12L is the world's first AI-powered handheld 12-lead ECG system, representing a paradigm shift in cardiac diagnostics. The device uses a unique single-cable design with five electrodes to acquire eight diagnostic-quality leads, powered by the proprietary KAI 12L artificial intelligence engine.
Key Specifications:
- Weight: Approximately 0.3 pounds (battery-operated)
- Design: Single-cable, reduced-lead configuration for maximum portability
- Clinical Validation: Peer-reviewed study published in Heart Rhythm O2 (August 2025) demonstrated 29% reduction in ECG acquisition time compared to conventional 12-lead systems (7.1 vs. 10 minutes, p<0.001)>
- Detection Capability: Over 4,000 cases of myocardial infarction and ischemia identified since launch
- Adoption: Deployed in more than 250 clinical practices across the United States; expanded into India, Australia, and New Zealand with European regulatory review underway
FDA-Cleared Determinations (as of January 2026): Total of 39 determinations, including:
- Rhythm modifiers: Short PR Interval, Atrial Bigeminy, Ventricular Bigeminy
- Axis-related morphology: Left Axis Deviation (LAD), Right Axis Deviation (RAD)
- Myocardial infarction and ischemia detection
- Multiple arrhythmia classifications
Kardia Pro & Enterprise Solutions
Kardia Pro: AI-powered clinical platform for healthcare providers enabling remote patient monitoring and early detection of AFib to prevent stroke. The platform analyzes patient data including weight, activity, and blood pressure to personalize heart profiles.
Regulatory Milestones & Achievements
FDA Clearances:
- 2014: First FDA clearance for AFib detection algorithm on mobile device
- 2017: KardiaBand becomes first FDA-cleared medical device accessory for Apple Watch
- 2020: Next-generation ECG algorithms cleared for wider arrhythmia detection
- 2024: Kardia 12L receives initial FDA clearance
- January 2026: KAI 12L AI engine cleared for 39 total cardiac determinations
Medicare Coverage:
- In 2025, the Centers for Medicare & Medicaid Services (CMS) approved Medicare payment for Kardia 12L in hospital outpatient settings, following the American Medical Association's establishment of Category III CPT codes in 2024
Industry Recognition:
- Named No. 1 Most Innovative Company in Artificial Intelligence by Fast Company (2018)
- Recognized globally for transforming cardiac care through AI and mobile technology
Leadership Team
- Chief Executive Officer: Priya Abani (leading company through FDA clearances and commercial expansion)
- Co-Founder & Chief Medical Officer: David Albert, MD (inventor of the company's core ECG technology)
- Chief Product Officer: Alfred Woo
- Chief Business Officer: Sanjay Voleti
- Chief Technology Officer: Siva Somayajula
- Chief Marketing Officer: Cora Locke
Board Members: Vinod Khosla (Khosla Ventures), Sebastian Thrun, Toby Cosgrove, Ranndy Kellogg (Omron), Nigel Blakeway, Thomas Westrick, Ryan Phillips
Clinical Evidence & Research
Northwestern Memorial Hospital Study (August 2025):
A peer-reviewed study published in Heart Rhythm O2 evaluated Kardia 12L in an electrophysiology clinic setting:
- Study Population: 50 patients (74% evaluated for atrial fibrillation/flutter, 6% for premature ventricular contractions)
- Time Efficiency: Kardia 12L acquisition time averaged 7.1 minutes vs. 10.0 minutes for standard 12L ECG (29% reduction, p<0.001)>
- Diagnostic Reliability: Only 5 patients required follow-up standard 12L ECG due to poor signal quality (n=2) or printer settings limiting QT interval measurement (n=3)
- Conclusion: Kardia 12L offers substantial time advantage without sacrificing diagnostic reliability
Strategic Positioning & Market Expansion
Geographic Expansion:
- United States: Over 250 clinical practices adopted; Medicare reimbursement established
- International: Launched in India, Australia, and New Zealand; European regulatory review underway for CE marking
Competitive Landscape:
- Apple: Integration of ECG functionality in Apple Watch Series 4+ (competitor and former partner via KardiaBand)
- Withings: ECG-enabled smartwatches at lower price points
- Traditional ECG Manufacturers: Philips, GE Healthcare, and other conventional 12-lead ECG device makers
Legal Challenges:
- Ongoing patent litigation with Apple Inc. regarding ECG technology and intellectual property rights
Company Information
Legal Name: AliveCor, Inc.
Founded: 2010
Headquarters: Mountain View, California, USA
Website: www.alivecor.com
Employee Count: Approximately 227 (estimated)
Estimated Revenue: $71.2 million (estimated, per Growjo)
Total Funding Raised: Over $108.5 million across 6 funding rounds
Investors: GE Healthcare, Omron Corporation, Khosla Ventures, Mayo Clinic, Qualcomm Ventures, WP Global Partners, Bold Capital Partners, Burrill & Company
Keywords: AliveCor, KardiaMobile, Kardia 12L, KAI 12L, AI ECG, artificial intelligence cardiology, mobile ECG, personal heart monitor, atrial fibrillation, AFib, bradycardia, tachycardia, FDA cleared, remote cardiac monitoring, Priya Abani, David Albert, Mountain View, Khosla Ventures, Omron, GE Healthcare, Series F, KardiaBand, Apple Watch, 39 cardiac determinations, Medicare CPT codes, Heart Rhythm O2, myocardial infarction detection, ischemia monitoring
